世界の抗体薬物複合体（ADC）治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Antibody Drug Conjugate Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z0371 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥565,500 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥848,250 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,131,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、抗体薬物複合体（ADC）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（イミュノメディクス技術、イミュノゲン技術、シアトル遺伝学技術、その他）、用途別市場規模（リンパ腫、白血病、多発性骨髄腫、皮膚がん、結腸がん、神経膠芽細胞腫、膵臓がん、前立腺がん、固形腫瘍、乳がん）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・抗体薬物複合体（ADC）治療の市場動向 ・企業の競争状況、市場シェア ・抗体薬物複合体（ADC）治療の種類別市場規模（イミュノメディクス技術、イミュノゲン技術、シアトル遺伝学技術、その他） ・抗体薬物複合体（ADC）治療の用途別市場規模（リンパ腫、白血病、多発性骨髄腫、皮膚がん、結腸がん、神経膠芽細胞腫、膵臓がん、前立腺がん、固形腫瘍、乳がん） ・抗体薬物複合体（ADC）治療の北米市場規模2016-2027（アメリカ、カナダ） ・抗体薬物複合体（ADC）治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・抗体薬物複合体（ADC）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・抗体薬物複合体（ADC）治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・抗体薬物複合体（ADC）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Bayer AG、Pfizer、Hoffman-Le Roche、Seattle Genetics、ImmunoGen、Genentech、Synthon Holding、Sanofi、Genmab、Amgen、Novartis、Eli Lilly） ・結論

Market Analysis and Insights: Global Antibody Drug Conjugate Therapeutics Market
The global Antibody Drug Conjugate Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antibody Drug Conjugate Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antibody Drug Conjugate Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antibody Drug Conjugate Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antibody Drug Conjugate Therapeutics market.

Global Antibody Drug Conjugate Therapeutics Scope and Market Size
Antibody Drug Conjugate Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Antibody Drug Conjugate Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Mmunomedics Technology
Immunogen Technology
Seattle Genetics Technology
Others

Segment by Application
Lymphoma
Leukemia
Multiple Myeloma
Skin Cancer
Colon Cancer
Glioblastoma
Pancreatic Cancer
Prostate Cancer
Solid Tumor

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Bayer AG
Pfizer
Hoffman-Le Roche
Seattle Genetics
ImmunoGen
Genentech
Synthon Holding
Sanofi
Genmab
Amgen

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody Drug Conjugate Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Mmunomedics Technology
1.2.3 Immunogen Technology
1.2.4 Seattle Genetics Technology
1.2.5 Others
1.3 Market by Application
1.3.1 Global Antibody Drug Conjugate Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Lymphoma
1.3.3 Leukemia
1.3.4 Multiple Myeloma
1.3.5 Skin Cancer
1.3.6 Colon Cancer
1.3.7 Glioblastoma
1.3.8 Pancreatic Cancer
1.3.9 Prostate Cancer
1.3.10 Solid Tumor
1.3.11 Breast Cancer
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Antibody Drug Conjugate Therapeutics Market Perspective (2016-2027)
2.2 Antibody Drug Conjugate Therapeutics Growth Trends by Regions
2.2.1 Antibody Drug Conjugate Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Antibody Drug Conjugate Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Antibody Drug Conjugate Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Antibody Drug Conjugate Therapeutics Industry Dynamic
2.3.1 Antibody Drug Conjugate Therapeutics Market Trends
2.3.2 Antibody Drug Conjugate Therapeutics Market Drivers
2.3.3 Antibody Drug Conjugate Therapeutics Market Challenges
2.3.4 Antibody Drug Conjugate Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Antibody Drug Conjugate Therapeutics Players by Revenue
3.1.1 Global Top Antibody Drug Conjugate Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Antibody Drug Conjugate Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Antibody Drug Conjugate Therapeutics Revenue
3.4 Global Antibody Drug Conjugate Therapeutics Market Concentration Ratio
3.4.1 Global Antibody Drug Conjugate Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugate Therapeutics Revenue in 2020
3.5 Antibody Drug Conjugate Therapeutics Key Players Head office and Area Served
3.6 Key Players Antibody Drug Conjugate Therapeutics Product Solution and Service
3.7 Date of Enter into Antibody Drug Conjugate Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Antibody Drug Conjugate Therapeutics Breakdown Data by Type
4.1 Global Antibody Drug Conjugate Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Type (2022-2027)

5 Antibody Drug Conjugate Therapeutics Breakdown Data by Application
5.1 Global Antibody Drug Conjugate Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Antibody Drug Conjugate Therapeutics Market Size (2016-2027)
6.2 North America Antibody Drug Conjugate Therapeutics Market Size by Type
6.2.1 North America Antibody Drug Conjugate Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Antibody Drug Conjugate Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Antibody Drug Conjugate Therapeutics Market Size by Type (2016-2027)
6.3 North America Antibody Drug Conjugate Therapeutics Market Size by Application
6.3.1 North America Antibody Drug Conjugate Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Antibody Drug Conjugate Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Antibody Drug Conjugate Therapeutics Market Size by Application (2016-2027)
6.4 North America Antibody Drug Conjugate Therapeutics Market Size by Country
6.4.1 North America Antibody Drug Conjugate Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Antibody Drug Conjugate Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Antibody Drug Conjugate Therapeutics Market Size (2016-2027)
7.2 Europe Antibody Drug Conjugate Therapeutics Market Size by Type
7.2.1 Europe Antibody Drug Conjugate Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Antibody Drug Conjugate Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Antibody Drug Conjugate Therapeutics Market Size by Type (2016-2027)
7.3 Europe Antibody Drug Conjugate Therapeutics Market Size by Application
7.3.1 Europe Antibody Drug Conjugate Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Antibody Drug Conjugate Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Antibody Drug Conjugate Therapeutics Market Size by Application (2016-2027)
7.4 Europe Antibody Drug Conjugate Therapeutics Market Size by Country
7.4.1 Europe Antibody Drug Conjugate Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Antibody Drug Conjugate Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Type
8.2.1 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Application
8.3.1 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Region
8.4.1 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Antibody Drug Conjugate Therapeutics Market Size (2016-2027)
9.2 Latin America Antibody Drug Conjugate Therapeutics Market Size by Type
9.2.1 Latin America Antibody Drug Conjugate Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Antibody Drug Conjugate Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Antibody Drug Conjugate Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Antibody Drug Conjugate Therapeutics Market Size by Application
9.3.1 Latin America Antibody Drug Conjugate Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Antibody Drug Conjugate Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Antibody Drug Conjugate Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Antibody Drug Conjugate Therapeutics Market Size by Country
9.4.1 Latin America Antibody Drug Conjugate Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Antibody Drug Conjugate Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Type
10.2.1 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Application
10.3.1 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Country
10.4.1 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Bayer AG
11.1.1 Bayer AG Company Details
11.1.2 Bayer AG Business Overview
11.1.3 Bayer AG Antibody Drug Conjugate Therapeutics Introduction
11.1.4 Bayer AG Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021)
11.1.5 Bayer AG Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Antibody Drug Conjugate Therapeutics Introduction
11.2.4 Pfizer Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 Hoffman-Le Roche
11.3.1 Hoffman-Le Roche Company Details
11.3.2 Hoffman-Le Roche Business Overview
11.3.3 Hoffman-Le Roche Antibody Drug Conjugate Therapeutics Introduction
11.3.4 Hoffman-Le Roche Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021)
11.3.5 Hoffman-Le Roche Recent Development
11.4 Seattle Genetics
11.4.1 Seattle Genetics Company Details
11.4.2 Seattle Genetics Business Overview
11.4.3 Seattle Genetics Antibody Drug Conjugate Therapeutics Introduction
11.4.4 Seattle Genetics Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021)
11.4.5 Seattle Genetics Recent Development
11.5 ImmunoGen
11.5.1 ImmunoGen Company Details
11.5.2 ImmunoGen Business Overview
11.5.3 ImmunoGen Antibody Drug Conjugate Therapeutics Introduction
11.5.4 ImmunoGen Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021)
11.5.5 ImmunoGen Recent Development
11.6 Genentech
11.6.1 Genentech Company Details
11.6.2 Genentech Business Overview
11.6.3 Genentech Antibody Drug Conjugate Therapeutics Introduction
11.6.4 Genentech Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021)
11.6.5 Genentech Recent Development
11.7 Synthon Holding
11.7.1 Synthon Holding Company Details
11.7.2 Synthon Holding Business Overview
11.7.3 Synthon Holding Antibody Drug Conjugate Therapeutics Introduction
11.7.4 Synthon Holding Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021)
11.7.5 Synthon Holding Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Antibody Drug Conjugate Therapeutics Introduction
11.8.4 Sanofi Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021)
11.8.5 Sanofi Recent Development
11.9 Genmab
11.9.1 Genmab Company Details
11.9.2 Genmab Business Overview
11.9.3 Genmab Antibody Drug Conjugate Therapeutics Introduction
11.9.4 Genmab Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021)
11.9.5 Genmab Recent Development
11.10 Amgen
11.10.1 Amgen Company Details
11.10.2 Amgen Business Overview
11.10.3 Amgen Antibody Drug Conjugate Therapeutics Introduction
11.10.4 Amgen Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021)
11.10.5 Amgen Recent Development
11.11 Novartis
11.11.1 Novartis Company Details
11.11.2 Novartis Business Overview
11.11.3 Novartis Antibody Drug Conjugate Therapeutics Introduction
11.11.4 Novartis Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021)
11.11.5 Novartis Recent Development
11.12 Eli Lilly
11.12.1 Eli Lilly Company Details
11.12.2 Eli Lilly Business Overview
11.12.3 Eli Lilly Antibody Drug Conjugate Therapeutics Introduction
11.12.4 Eli Lilly Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021)
11.12.5 Eli Lilly Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Antibody Drug Conjugate Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Mmunomedics Technology
Table 3. Key Players of Immunogen Technology
Table 4. Key Players of Seattle Genetics Technology
Table 5. Key Players of Others
Table 6. Global Antibody Drug Conjugate Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Antibody Drug Conjugate Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Antibody Drug Conjugate Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Antibody Drug Conjugate Therapeutics Market Share by Regions (2016-2021)
Table 10. Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Antibody Drug Conjugate Therapeutics Market Share by Regions (2022-2027)
Table 12. Antibody Drug Conjugate Therapeutics Market Trends
Table 13. Antibody Drug Conjugate Therapeutics Market Drivers
Table 14. Antibody Drug Conjugate Therapeutics Market Challenges
Table 15. Antibody Drug Conjugate Therapeutics Market Restraints
Table 16. Global Antibody Drug Conjugate Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Antibody Drug Conjugate Therapeutics Market Share by Players (2016-2021)
Table 18. Global Top Antibody Drug Conjugate Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antibody Drug Conjugate Therapeutics as of 2020)
Table 19. Ranking of Global Top Antibody Drug Conjugate Therapeutics Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Antibody Drug Conjugate Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Antibody Drug Conjugate Therapeutics Product Solution and Service
Table 23. Date of Enter into Antibody Drug Conjugate Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Antibody Drug Conjugate Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Type (2016-2021)
Table 27. Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Antibody Drug Conjugate Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Application (2016-2021)
Table 31. Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Antibody Drug Conjugate Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Antibody Drug Conjugate Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Antibody Drug Conjugate Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Antibody Drug Conjugate Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Antibody Drug Conjugate Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Antibody Drug Conjugate Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Antibody Drug Conjugate Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Antibody Drug Conjugate Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Antibody Drug Conjugate Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Antibody Drug Conjugate Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Antibody Drug Conjugate Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Antibody Drug Conjugate Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Antibody Drug Conjugate Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Antibody Drug Conjugate Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Antibody Drug Conjugate Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Antibody Drug Conjugate Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Antibody Drug Conjugate Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Antibody Drug Conjugate Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 63. Bayer AG Company Details
Table 64. Bayer AG Business Overview
Table 65. Bayer AG Antibody Drug Conjugate Therapeutics Product
Table 66. Bayer AG Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021) & (US$ Million)
Table 67. Bayer AG Recent Development
Table 68. Pfizer Company Details
Table 69. Pfizer Business Overview
Table 70. Pfizer Antibody Drug Conjugate Therapeutics Product
Table 71. Pfizer Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021) & (US$ Million)
Table 72. Pfizer Recent Development
Table 73. Hoffman-Le Roche Company Details
Table 74. Hoffman-Le Roche Business Overview
Table 75. Hoffman-Le Roche Antibody Drug Conjugate Therapeutics Product
Table 76. Hoffman-Le Roche Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021) & (US$ Million)
Table 77. Hoffman-Le Roche Recent Development
Table 78. Seattle Genetics Company Details
Table 79. Seattle Genetics Business Overview
Table 80. Seattle Genetics Antibody Drug Conjugate Therapeutics Product
Table 81. Seattle Genetics Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021) & (US$ Million)
Table 82. Seattle Genetics Recent Development
Table 83. ImmunoGen Company Details
Table 84. ImmunoGen Business Overview
Table 85. ImmunoGen Antibody Drug Conjugate Therapeutics Product
Table 86. ImmunoGen Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021) & (US$ Million)
Table 87. ImmunoGen Recent Development
Table 88. Genentech Company Details
Table 89. Genentech Business Overview
Table 90. Genentech Antibody Drug Conjugate Therapeutics Product
Table 91. Genentech Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021) & (US$ Million)
Table 92. Genentech Recent Development
Table 93. Synthon Holding Company Details
Table 94. Synthon Holding Business Overview
Table 95. Synthon Holding Antibody Drug Conjugate Therapeutics Product
Table 96. Synthon Holding Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021) & (US$ Million)
Table 97. Synthon Holding Recent Development
Table 98. Sanofi Company Details
Table 99. Sanofi Business Overview
Table 100. Sanofi Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021) & (US$ Million)
Table 101. Sanofi Recent Development
Table 102. Genmab Company Details
Table 103. Genmab Business Overview
Table 104. Genmab Antibody Drug Conjugate Therapeutics Product
Table 105. Genmab Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021) & (US$ Million)
Table 106. Genmab Recent Development
Table 107. Amgen Company Details
Table 108. Amgen Business Overview
Table 109. Amgen Antibody Drug Conjugate Therapeutics Product
Table 110. Amgen Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021) & (US$ Million)
Table 111. Amgen Recent Development
Table 112. Novartis Company Details
Table 113. Novartis Business Overview
Table 114. Novartis Antibody Drug Conjugate Therapeutics Product
Table 115. Novartis Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021) & (US$ Million)
Table 116. Novartis Recent Development
Table 117. Eli Lilly Company Details
Table 118. Eli Lilly Business Overview
Table 119. Eli Lilly Antibody Drug Conjugate Therapeutics Product
Table 120. Eli Lilly Revenue in Antibody Drug Conjugate Therapeutics Business (2016-2021) & (US$ Million)
Table 121. Eli Lilly Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antibody Drug Conjugate Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Mmunomedics Technology Features
Figure 3. Immunogen Technology Features
Figure 4. Seattle Genetics Technology Features
Figure 5. Others Features
Figure 6. Global Antibody Drug Conjugate Therapeutics Market Share by Application: 2020 VS 2027
Figure 7. Lymphoma Case Studies
Figure 8. Leukemia Case Studies
Figure 9. Multiple Myeloma Case Studies
Figure 10. Skin Cancer Case Studies
Figure 11. Colon Cancer Case Studies
Figure 12. Glioblastoma Case Studies
Figure 13. Pancreatic Cancer Case Studies
Figure 14. Prostate Cancer Case Studies
Figure 15. Solid Tumor Case Studies
Figure 16. Breast Cancer Case Studies
Figure 17. Antibody Drug Conjugate Therapeutics Report Years Considered
Figure 18. Global Antibody Drug Conjugate Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 19. Global Antibody Drug Conjugate Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 20. Global Antibody Drug Conjugate Therapeutics Market Share by Regions: 2020 VS 2027
Figure 21. Global Antibody Drug Conjugate Therapeutics Market Share by Regions (2022-2027)
Figure 22. Global Antibody Drug Conjugate Therapeutics Market Share by Players in 2020
Figure 23. Global Top Antibody Drug Conjugate Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antibody Drug Conjugate Therapeutics as of 2020
Figure 24. The Top 10 and 5 Players Market Share by Antibody Drug Conjugate Therapeutics Revenue in 2020
Figure 25. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Type (2016-2021)
Figure 26. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Type (2022-2027)
Figure 27. North America Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. North America Antibody Drug Conjugate Therapeutics Market Share by Type (2016-2027)
Figure 29. North America Antibody Drug Conjugate Therapeutics Market Share by Application (2016-2027)
Figure 30. North America Antibody Drug Conjugate Therapeutics Market Share by Country (2016-2027)
Figure 31. United States Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Canada Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Europe Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Europe Antibody Drug Conjugate Therapeutics Market Share by Type (2016-2027)
Figure 35. Europe Antibody Drug Conjugate Therapeutics Market Share by Application (2016-2027)
Figure 36. Europe Antibody Drug Conjugate Therapeutics Market Share by Country (2016-2027)
Figure 37. Germany Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. France Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. U.K. Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Italy Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Russia Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Nordic Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Share by Type (2016-2027)
Figure 45. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Share by Application (2016-2027)
Figure 46. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Share by Region (2016-2027)
Figure 47. China Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Japan Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. South Korea Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Southeast Asia Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. India Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Australia Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Latin America Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Latin America Antibody Drug Conjugate Therapeutics Market Share by Type (2016-2027)
Figure 55. Latin America Antibody Drug Conjugate Therapeutics Market Share by Application (2016-2027)
Figure 56. Latin America Antibody Drug Conjugate Therapeutics Market Share by Country (2016-2027)
Figure 57. Mexico Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Brazil Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Share by Type (2016-2027)
Figure 61. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Share by Application (2016-2027)
Figure 62. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Share by Country (2016-2027)
Figure 63. Turkey Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 64. Saudi Arabia Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 65. UAE Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 66. Bayer AG Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2016-2021)
Figure 67. Pfizer Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2016-2021)
Figure 68. Hoffman-Le Roche Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2016-2021)
Figure 69. Seattle Genetics Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2016-2021)
Figure 70. ImmunoGen Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2016-2021)
Figure 71. Genentech Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2016-2021)
Figure 72. Synthon Holding Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2016-2021)
Figure 73. Sanofi Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2016-2021)
Figure 74. Genmab Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2016-2021)
Figure 75. Amgen Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2016-2021)
Figure 76. Novartis Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2016-2021)
Figure 77. Eli Lilly Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2016-2021)
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed

---